Prevail Innovative Wealth Advisors LLC Grows Stock Holdings in CVS Health Corporation $CVS

Prevail Innovative Wealth Advisors LLC lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 94.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,611 shares of the pharmacy operator’s stock after acquiring an additional 11,465 shares during the quarter. Prevail Innovative Wealth Advisors LLC’s holdings in CVS Health were worth $1,780,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CVS. Norges Bank purchased a new position in CVS Health during the 2nd quarter worth $1,358,698,000. Invesco Ltd. lifted its holdings in shares of CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after buying an additional 3,118,626 shares during the period. Vanguard Group Inc. grew its position in shares of CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after buying an additional 2,063,737 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of CVS Health by 153.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock valued at $214,240,000 after buying an additional 1,878,217 shares during the period. Finally, Panagora Asset Management Inc. lifted its stake in CVS Health by 2,675.7% in the second quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator’s stock worth $77,033,000 after acquiring an additional 1,076,509 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Morgan Stanley boosted their price objective on shares of CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Barclays lifted their price target on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, TD Cowen upped their price objective on CVS Health from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $94.91.

CVS Health Price Performance

Shares of CVS opened at $77.91 on Friday. The company has a 50 day moving average of $78.49 and a two-hundred day moving average of $77.60. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The company has a market cap of $99.12 billion, a price-to-earnings ratio of 56.46, a price-to-earnings-growth ratio of 0.81 and a beta of 0.49.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing – Here’s Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health (NYSE:CVS) Price Target to $97.00

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.